Drug intelligence / Profile preview

mixed amphetamine salts (Takeda, 0454e2)

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

Mixed amphetamine salts is a central nervous system (CNS) stimulant composed of four different amphetamine salts: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate. It is primarily indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The drug works by increasing the synaptic concentrations of norepinephrine and dopamine through several mechanisms: it acts as a competitive inhibitor of the dopamine transporter (DAT) and norepinephrine transporter (NET), promotes the release of these neurotransmitters from presynaptic neurons, and inhibits their sequestration into vesicles via the vesicular monoamine transporter 2 (VMAT2). Additionally, it acts as an agonist at the trace amine-associated receptor 1 (TAAR1). The mixture typically contains a 3:1 ratio of dextroamphetamine to levoamphetamine isomers, which is intended to provide a balanced therapeutic effect on focus and alertness while managing peripheral side effects.

Brand names
AdderallAdderall XRMydayisAdzenys XR-ODTDyanavel XR
Other names
MASMAS-XRamphetamine salt comboamphetamine aspartate/amphetamine sulfate/dextroamphetamine saccharate/dextroamphetamine sulfate
02

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)TAAR1 (Trace amine-associated receptor 1)VMAT2 (Vesicular monoamine transporter 2)

Beyond the preview

Go deeper on mixed amphetamine salts (Takeda, 0454e2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mixed amphetamine salts (Takeda, 0454e2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call